About Paratek

We are a pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines that are designed to save lives and alleviate suffering. Our lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians.

We believe omadacycline will be used in the emergency room, hospital, and community settings. We have designed omadacycline to provide significant advantages over existing antibiotics, including activity against resistant bacteria, broad spectrum of coverage, intravenous, or IV, and oral formulations with once-daily dosing, and a favorable safety and tolerability profile. We believe that it will become the primary antibiotic choice of physicians for use as a first-line monotherapy for acute bacterial skin and skin structure infections, or ABSSSI, community-acquired bacterial pneumonia, or CABP, urinary tract infections, or UTI, and other serious community-acquired bacterial infections.

Our second most advanced product candidate, WC 3035, is a novel tetracycline-derived compound designed for use in the treatment of acne and rosacea. WC 3035 has demonstrated favorable anti-inflammatory activity, narrow-spectrum antibacterial activity relative to other tetracycline-derived molecules, oral bioavailability, and favorable pharmacokinetic, or PK, properties which we believe make it particularly well-suited for the treatment of acne and rosacea in the community setting. We have licensed rights to WC 3035 for the treatment of acne and rosacea in the United States to a subsidiary of Actavis (formerly Warner Chilcott), while retaining rights in the rest of the world. Actavis is responsible for the clinical development of WC 3035 for the treatment of acne in the United States, following a successful phase 2 clinical trial; a phase 3 clinical trial is planned for the second half of 2014 of this product candidate for this indication.

In addition to omadacycline and WC 3035, we have advanced a series of product candidates through to proof of concept in animal models. We designed these next generation, tetracycline-derived, new molecular entities using our proprietary drug development platform, and incorporated the recognized immune-modulation, anti-inflammatory, and other properties of the tetracycline class. We believe that, based on our preclinical testing to date, the potential for these small molecule therapies to treat debilitating neurological and inflammatory diseases such as multiple sclerosis, spinal muscular atrophy, rheumatoid arthritis, and inflammatory bowel disease, is promising. In addition, we have an early-stage program focused on the treatment of Clostridium difficile associated diarrhea, as well as a program focused on important animal health diseases.


Senior Management Team

  • Michael F. Bigham, MBA
    Chairman of the Board and Chief Executive Officer

  • Evan Loh, MD
    President, Chief Medical Officer, and Director
    > Led Tygacil development
  • Beverly A. Armstrong, JD, MBA
    Vice President, Administration, Chief Compliance Officer and General Counsel
  • Kathryn M. Boxmeyer, MBA
    Vice President, Chief Financial Officer and Treasurer
  • Sean M. Johnston, Ph.D
    Vice President, Manufacturing
  • Dennis P. Molnar, MBA
    Senior Vice President, Corporate Development
  • S. Ken Tanaka, Ph.D
    Vice President-Research & Development
    > Developed clarithromycin, temofloxacin

The Paratek team enjoys a broad range of management experience developed across the biotechnology and pharmaceutical sectors.

Board of Directors

Michael F. Bigham, MBA, was appointed Chief Executive Officer and Chairman of the Board of Directors in June 2014. Mr. Bigham is a Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare, and has more than 25 years of senior leadership experience in the biopharmaceutical industry.  He currently serves on the boards of Avedro and Secure EDI and has held several directorships including Avila Therapeutics where he was the founding Chairman and CEO, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals and Valeritas.  Michael was formerly Vice Chairman of Corixa Corporation, a publicly-traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa.  Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer.  Before joining Gilead, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Michael qualified as a CPA before completing his MBA at Stanford University.

Evan Loh, MD, was appointed President in June 2014, serves as our Chief Medical Officer, and also serves on our board of Directors. From October 2009 to January 2012, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Prior to joining Pfizer, from January 2007 to October 2009, Dr. Loh was Vice President, Clinical Research & Development at Wyeth, where he was responsible for leadership and strategic oversight of clinical development efforts across multiple therapeutic areas throughout the world. He is the 2006 recipient of the Heroes of Chemistry Award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.

Richard Lim, MBA, joined our board of directors in March of 2014.  Mr. Lim is a Partner at Omega Funds and has over 20 years in principal investment and strategic consulting, all within life science and healthcare. He was previously a General Partner at MVM Life Science Partners, a life science focused venture capital firm with $500 million under management; he founded MVM’s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), a private equity firm with $1.7bn under management, where he specialized in healthcare growth capital and leveraged transactions. Prior to SKM (now known as Apax Partners Inc.), Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than 3 dozen small and large biotechnology firms. He was also an Associate with M&A investment bank BT Wolfensohn. He has served on a number of boards in biotechnology, specialty pharmaceuticals, and medical device companies. He serves as a catalyst advisor of the Deshpande Center at the Massachusetts Institute of Technology. He earned AB and MBA degrees from Harvard University.









Coming soon.

To contact Paratek investor relations, please email us at ir@paratekpharm.com.  


Poster Presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 9-12, 2012

Pharmacokinetics of [14C]-labeled Omadacycline (PTK 0796) in Healthy Male Subjects.

Pharmacokinetics of Omadacycline (PTK0796) in Subjects with Hepatic Impairment

Posters Presented at 22nd European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), March 30-April 3, 2011

Safety and Efficacy of PTK 796 (Omadacycline) as Treatment of Complicated Skin and Soft Tissue Infection (cSSTI)

Metabolic Stability of PTK 796 (Omadacycline)

A Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Formulations of PTK 0796 in Healthy Subjects

Lack of Interaction of PTK 0796 (Omadacycline) with Human Transporter

Antimicrobial Activity of PTK 0796 (Omadacycline) and Comparator Agents Against Contemporary Pathogens Commonly Associated with Community-Acquired Respiratory Tract Infections Collected During 2011 from the European Union

Antimicrobial Activity of PTK 0796 (Omadacycline) Tested Against Gram-Positive Organisms Isolated from European Hospitals in 2011

Poster Presented at 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, 2011

Omadacycline (PTK796) Mechanism of Action Studies by Using InVitro Protein Synthesis Inhibition Assay and Molecular Modeling

Posters Presented at 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) / 27th International Congress of Chemotheraphy (ICC), May 7-10, 2011

In a phase 2 complicated skin and soft tissue infections trial, outcomes assessed early in the course of therapy were consistent with outcomes 10-17 days after completing therapy with either omadacycline (OMC; PTK796) or linezolid, Poster P1528

Comparative efficacy of omadacycline (PTK796) in a lethal Streptococcus pneumoniae and Staphylococcus aureus pneumonia model, Poster P1074

In vitro activity of omadacycline (PTK796) in broth plus lung surfactant or human serum, Poster P1141

Posters Presented at 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 12-15, 2010

Efficacy of PTK796 in a Rat MRSA Infected Endocarditis (IE) Model, Poster B-069

Studies on the Mechanism of Resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumonia, Poster C1-1413

In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe, Poster E-1569

Antimicrobial Activity of PTK 0796 Tested against Gram-Positive Organisms Causing Bloodstream Infections in 2009, Poster E-1588

Pharmacokinetics of Intravenous and Oral PTK796, A New Aminomethylcycline Antibiotic, Poster K-124

Identification and Susceptibility of Pathogens Isolated from Patients with Complicated Skin and Skin Structure Infections (cSSSI): Results of a PTK0796 (PTK) Phase 2 Clinical Trial, Poster L1-1760

Poster Presented at Annual European League Against Rheumatism (EULAR) Congress, June 10-13, 2009

Inhibition of Murine Collagen-Induced Arthritis by Non-Antibacterial Tetracycline Derivatives

Posters Presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 25-28, 2008

Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in Complicated Skin and Skin Structure Infections Following IV and Oral Step Down Therapy, Poster L-1515b

Efficacy of MAR Inhibitors in a Pseudomonas aeruginosa Pneumonia Model, Poster F1-3958

Poster Presented at 15th International Inflammation Research Association Conference, September 21-24, 2008

Therapeutic Inhibition of Murine Collagen-Induced Arthritis by Non-Antibacterial Derivatives of Minocycline

Poster Presented at 60th Annual Meeting of the American Academy of Neurology, April 12-19, 2008

A Tetracycline That Corrects SMN2 Splicing for Potential Treatment of Spinal Muscular Atrophy (SMA)

Poster Presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 18, 2007

A Novel Anti-virulence Approach for Treatment of Pneumonia Caused by Pseudomonas aeruginosa, Poster F2-968a

Poster Presented at 107th General Meeting of the American Society for Microbiology (ASM), May 22, 2007

Small Molecule Inhibitors of Yersinia pseudotuberculosis Transcription Factor LcrF (VirF) Attenuate Virulence and Limit Infection in a Murine Pneumonia Model, Poster A-030

Posters Presented at 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 30, 2006

Antistaphylococcal Activity of MK-2764 / PTK 0796 Compared to Other Agents, Poster F1-1971

In Vitro Activity of MK-2764 / PTK 0796 Against Legionella spp., Poster F1-1972

Pharmacokinetic/Pharmacodynamic Profile of MK-2764 / PTK 0796 against S. pneumoniae in a Murine Pneumonia Model, Poster F1-1973

In Vivo Pharmacodynamics of MK-2764 / PTK 0796 Against Various Gram-positive and Gram-negative Bacteria in the Thighs of Neutropenic and Normal Mice, Poster F1-1974

Posters Presented at 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 15, 2003

In Vitro Activity of BAY 73-6944/PTK 0796 Against Gram-Positive and Gram-Negative Organisms, Poster F-754

Evaluation of BAY 73-6944/PTK 0796 in Experimental Models of Infections Caused by Gram-Positive and Gram-Negative Pathogens, Poster F-757

The Efficacy of BAY 73-6944/PTK 0796 in Murine Models of Streptococcus pneumoniae Infections, Poster F-758

BAY 73-6944/PTK 0796: In Vitro Potency and Spectrum of Activity Compared to Ten Other Antimicrobial Compounds, Poster F-753

BAY 73-6944/PTK 0796: Effects of Environmental Variation on MICs and Confirmation of Disk Mass, Poster F-756

Pharmacokinetics of BAY 73-6944/PTK 0796 in Mouse, Rat and Cynomolgus Monkey, Poster F-759

The Activity of BAY 73-6944/PTK 0796 Against Tetracycline Resistance, Poster F-752

In Vitro Assessment of Plasma Protein Binding and Metabolic Stability of BAY 73-6944/PTK 0796, Poster F-760

The Mechanism of Action of BAY 73-6944/PTK 0796, Poster F-751

BAY 73-6944/PTK 0796 and other Novel Tetracycline Derivatives Exhibiting Potent in vitro and in vivo Activities Against Antibiotic Resistant Gram-Positive Bacteria, Poster F-755


Paratek Pharmaceuticals, Inc.

75 Kneeland Street
Boston, MA 02111
Phone: (617) 275-0040
Fax: (617) 275-0039


We are looking for highly motivated, bright, and committed individuals to join our team. If you would like to be considered for positions at Paratek, please submit your resume by email to: hr@paratekpharm.com.

Resumes and cover letters may also be sent to:
Paratek Pharmaceuticals, Inc.
Attn: Human Resources
75 Kneeland Street
Boston, MA 02111
Fax: (617) 275-0039

Paratek Pharmaceuticals, Inc. is an Equal Opportunity Employer.




Via MBTA: Take Red Line to South Station. Go left onto Atlantic Avenue. Go right onto Kneeland Street. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left.

From Mass Turnpike East: Follow turnpike East to exit 24a/SouthStation, and go left onto Kneeland Street off the exit ramp. Enter 75 Kneeland Street and take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)

From 93 North: Take exit 20, follow signs for South Station. Make a left at the fourth stop light onto Kneeland Street. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)

From 93 South: Take exit 23/Purchase Street, as you come out of the tunnel follow roadway as it winds through construction and becomes Purchase St. Continue through financial district on Purchase street across Congress, Summer and Lincoln Streets. Continue along Purchase Street as you approach Chinatown the road becomes Surface Artery, continue until the light at Kneeland Street and make a left onto Kneeland. Enter 75 Kneeland Street; take the elevator to the 6th floor. We are through the door on the left. (Parking instructions are given below.)

Parking (on Tyler): From Kneeland Street, go to Tyler Street. Make a right and park on the left at the open-air parking lot.

Parking (at New England Medical Center): Continue on Kneeland to Washington Street. Make a left and follow signs for Parking.